Accepted Article
PROF. RONALD FEITOSA PINHEIRO (Orcid ID : 0000-0002-7965-1409)
Article type
: Letter to the Editor
Letter to the editor regarding the article:
Valka J, Vesela J, Votavova H, Dostalova-Merkerova M, Horakova Z, Campr V, Brezinova J, Zemanova Z, Jonasova A, Cermak J, Belickova M. Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome. Eur J Haematol. 2017 Jul 5. doi: 10.1111/ejh.12920. [Epub ahead of print].
Expression of DNA repair genes are important molecular findings in CD34+ stemcells of Myelodysplastic Sydrome
Howard L. Ribeiro Junior 1, 2, 3; Allan Rodrigo Soares Maia1, 2; Roberta Taiane G. de Oliveira1, 2; Antônio Wesley Araújo dos Santos1, 2; Marília Braga Costa1, 2; Izabelle Rocha Farias1, 2; Daniela de Paula Borges1, 2; Silvia Maria M. Magalhães1, 2 and Ronald F. Pinheiro1, 2, 3, *
1
Cancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil.
2
Post-Graduate Program in Medical Science, Federal University of Ceara, Fortaleza, Ceara, Brazil.
3
Post-Graduate Program of Pathology, Federal University of Ceara, Fortaleza, Ceara, Brazil.
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ejh.12966 This article is protected by copyright. All rights reserved.
Accepted Article
* Corresponding author: Ronald Feitosa Pinheiro, MD, PhD Federal University of Ceara, Center for Research and Drug Development (NPDM) R. Coronel Nunes de Melo, 1000 - 2° andar - CEP 60430-275 Rodolfo Teófilo - Fortaleza - CE - Brazil Tel.: +55-85-3366-8075; Fax: +55-85-3366-8623 E-Mail: [email protected]; [email protected]. To the editor, We read with great interest the study of Valka et al. [1], recently published and we would like to reinforce the importance of DNA repair genes in the pathogenesis of myelodysplastic syndrome (MDS). The authors monitored and detected a differential expression of panel containing 84 DNA repair-associated genes in samples of CD34+ cells of MDS patients [1]. Here, we would like to complement the Valka et al. [1] study with our new recent analyzes of gene expression in a panel of 14 DNA repair genes (ATM, BRCA1, BRCA2, RAD51, XRCC5, XRCC6, LIG4, XPA, XPC, XPD/ERCC2, XPF/ERCC4, XPG/ERCC5, CSA/ERCC8 and CSB/ERCC6) in CD34+ stem cell samples, using quantitative PCR methodologies, and it’s relation with clinical laboratory variables of Brazilian MDS patients. In recent years (2013 to 2017), our research group has made efforts to study the role of DNA repair genes in etiology, prognosis and susceptibility of MDS [2-6]. At this moment, we are detecting that some DNA repair genes are significantly down-regulated in CD34+ hematopoietic stem cells (HSC) of MDS patients (ATM and XPG) and when stratified according to poor prognosis variables, such as the presence of dysgranulopoiesis (XPC, XPF and XPG), normo+hypercellular bone marrow (XPG), blasts count (>5%) (BRCA1, BRCA2, RAD51 and XPF), abnormal karyotype (XPD and XPF), IPSS-R higher risk (Intermediate + Poor + Very Poor) (XPA and XPC), death (BRCA1 and BRCA2) and AML evolution (BRCA2) (p
PROF. RONALD FEITOSA PINHEIRO (Orcid ID : 0000-0002-7965-1409)
Article type
: Letter to the Editor
Letter to the editor regarding the article:
Valka J, Vesela J, Votavova H, Dostalova-Merkerova M, Horakova Z, Campr V, Brezinova J, Zemanova Z, Jonasova A, Cermak J, Belickova M. Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome. Eur J Haematol. 2017 Jul 5. doi: 10.1111/ejh.12920. [Epub ahead of print].
Expression of DNA repair genes are important molecular findings in CD34+ stemcells of Myelodysplastic Sydrome
Howard L. Ribeiro Junior 1, 2, 3; Allan Rodrigo Soares Maia1, 2; Roberta Taiane G. de Oliveira1, 2; Antônio Wesley Araújo dos Santos1, 2; Marília Braga Costa1, 2; Izabelle Rocha Farias1, 2; Daniela de Paula Borges1, 2; Silvia Maria M. Magalhães1, 2 and Ronald F. Pinheiro1, 2, 3, *
1
Cancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil.
2
Post-Graduate Program in Medical Science, Federal University of Ceara, Fortaleza, Ceara, Brazil.
3
Post-Graduate Program of Pathology, Federal University of Ceara, Fortaleza, Ceara, Brazil.
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ejh.12966 This article is protected by copyright. All rights reserved.
Accepted Article
* Corresponding author: Ronald Feitosa Pinheiro, MD, PhD Federal University of Ceara, Center for Research and Drug Development (NPDM) R. Coronel Nunes de Melo, 1000 - 2° andar - CEP 60430-275 Rodolfo Teófilo - Fortaleza - CE - Brazil Tel.: +55-85-3366-8075; Fax: +55-85-3366-8623 E-Mail: [email protected]; [email protected]. To the editor, We read with great interest the study of Valka et al. [1], recently published and we would like to reinforce the importance of DNA repair genes in the pathogenesis of myelodysplastic syndrome (MDS). The authors monitored and detected a differential expression of panel containing 84 DNA repair-associated genes in samples of CD34+ cells of MDS patients [1]. Here, we would like to complement the Valka et al. [1] study with our new recent analyzes of gene expression in a panel of 14 DNA repair genes (ATM, BRCA1, BRCA2, RAD51, XRCC5, XRCC6, LIG4, XPA, XPC, XPD/ERCC2, XPF/ERCC4, XPG/ERCC5, CSA/ERCC8 and CSB/ERCC6) in CD34+ stem cell samples, using quantitative PCR methodologies, and it’s relation with clinical laboratory variables of Brazilian MDS patients. In recent years (2013 to 2017), our research group has made efforts to study the role of DNA repair genes in etiology, prognosis and susceptibility of MDS [2-6]. At this moment, we are detecting that some DNA repair genes are significantly down-regulated in CD34+ hematopoietic stem cells (HSC) of MDS patients (ATM and XPG) and when stratified according to poor prognosis variables, such as the presence of dysgranulopoiesis (XPC, XPF and XPG), normo+hypercellular bone marrow (XPG), blasts count (>5%) (BRCA1, BRCA2, RAD51 and XPF), abnormal karyotype (XPD and XPF), IPSS-R higher risk (Intermediate + Poor + Very Poor) (XPA and XPC), death (BRCA1 and BRCA2) and AML evolution (BRCA2) (p
